Abstract
Abstract
Background
Patient outcomes following low-trauma hip fracture are suboptimal resulting in increased healthcare costs and poor functional outcomes at 1 year. Providing early and intensive in-hospital physiotherapy could help improve patient outcomes and reduce costs following hip fracture surgery. The HIP fracture Supplemental Therapy to Enhance Recovery (HIPSTER) trial will compare usual care physiotherapy to intensive in-hospital physiotherapy for patients following hip fracture surgery. The complex environments in which the intervention is implemented present unique contextual challenges that may impact intervention effectiveness. This study aims to complete a process evaluation to identify barriers and facilitators to implementation and explore the patient, carer and clinician experience of intensive therapy following hip fracture surgery.
Methods and analysis
The process evaluation is embedded within a two-arm randomised, controlled, assessor-blinded trial recruiting 620 participants from eight Australian hospitals who have had surgery for a hip fracture sustained via a low-trauma injury. A theory-based mixed method process evaluation will be completed in tandem with the HIPSTER trial. Patient and carer semi-structured interviews will be completed at 6 weeks following hip fracture surgery. The clinician experience will be explored through online surveys completed pre- and post-implementation of intensive therapy and mapped to domains of the Theoretical Domains Framework (TDF). Translation and behaviour change success will be assessed using the Reach Effectiveness-Adoption Implementation Maintenance (RE-AIM) framework and a combination of qualitative and quantitative data collection methods. These data will assist with the development of an Implementation Toolkit aiding future translation into practice.
Discussion
The embedded process evaluation will help understand the interplay between the implementation context and the intensive therapy intervention following surgery for low-trauma hip fracture. Understanding these mechanisms, if effective, will assist with transferability into other contexts and wider translation into practice.
Trial registration
ACTRN 12622001442796.
Funder
Medical Research Future Fund
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Cooper C, Cole Z, Holroyd C, Earl S, Harvey NC, Dennison EM, et al. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int. 2011;22:1277–88.
2. Ireland AW, Kelly PJ, Cumming RG. State of origin: Australian states use widely different resources for hospital management of hip fracture, but achieve similar outcomes. Aust Health Rev. 2015;40(2):141–8.
3. Australian and New Zealand Hip Fracture Registry. ANZHFR Annual Report of Hip Fracture Care 2019. Australian and New Zealand Hip Fracture Registry, August 2019.
4. Australian and New Zealand Hip Fracture Registry. ANZHFR Annual Report of Hip Fracture Care 2021. Australian and New Zealand Hip Fracture Registry Australia, September 2021.
5. Veronese N, Maggi S. Epidemiology and social costs of hip fracture. Injury. 2018;49(8):1458–60.